Global Montelukast Intermediate Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Application;

Asthma , Allergic Rhinitis, Bronchospasm, and Urticaria.

By Geography;

North America, Europe, Asia Pacific, Middle East and Africa and Latin America - Report Timeline (2021 - 2031).
Report ID: Rn896896435 Published Date: January, 2025 Updated Date: February, 2025

Introduction

Global Montelukast Intermediate Market (USD Million), 2021 - 2031

In the year 2024, the Global Montelukast Intermediate Market was valued at USD 4.56 million. The size of this market is expected to increase to USD 6.12 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 4.3%.

Montelukast, classified as a leukotriene receptor antagonist (LTRA), serves as a vital medication in preventing asthma-related symptoms such as wheezing, breathing difficulties, chest tightness, and coughing. Additionally, it finds application in the treatment of both seasonal and perennial allergic rhinitis. The market for Montelukast experiences significant growth driven by several key factors. Firstly, the escalating global prevalence of asthma, bronchospasm, allergic rhinitis, and urticaria underscores the increasing demand for medications like Montelukast. Furthermore, the expanding pharmaceutical industry, coupled with rising demand from manufacturers of active pharmaceutical ingredients (APIs), contributes to market growth. Additionally, the expiration of Montelukast patents, along with the growing presence of generic alternatives, further fuels market expansion.

However, certain challenges pose potential hindrances to market growth. Stringent regulatory policies, aimed at ensuring the safety and efficacy of pharmaceutical products, may present barriers to market entry and expansion. Moreover, the high cost associated with manufacturing building blocks for active pharmaceutical ingredients could deter market growth during the forecast period. Despite these challenges, the increasing demand for Montelukast driven by the rising prevalence of respiratory conditions suggests continued market opportunities, albeit with the need for strategic adaptation to regulatory requirements and cost constraints.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Application
    2. Market Snapshot, By Region
  4. Global Montelukast Intermediate Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Rising Prevalence of Respiratory Diseases
        2. Growing Geriatric Population
        3. Expansion of Indications
        4. Increasing Awareness and Healthcare Expenditure
        5. Technological Advancements in Manufacturing
      2. Restraints
        1. Patent Expiry and Generic Competition
        2. Regulatory Challenges
        3. Adverse Effects and Safety Concerns
        4. Economic Instability
        5. Increasing Preference for Combination Therapies
      3. Opportunities
        1. Emerging Markets
        2. Personalized Medicine
        3. Strategic Collaborations and Partnerships
        4. Focus on Pediatric Indications
        5. Investment in Research and Development
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market SegmentationCompetitive Landscape
    1. Global Montelukast Intermediate Market, By Application, 2021 - 2031 (USD Million)
      1. Asthma
      2. Allergic Rhinitis
      3. Bronchospasm
      4. Urticaria
    2. Global Montelukast Intermediate Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Company Profiles
    1. VIVAN Life Sciences
    2. P.G. Shah & Co
    3. Manus Aktteva Biopharma LLP
    4. Ortin Laboratories Limited
  7. Analyst Views
  8. Future Outlook of the Market